EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting Transcriptional Coactivators p300/CBP: Small-Molecule Inhibitors or Bifunctional Proximity-Inducing Modalities?

Zonglong Chen iD, Xun Huang, Yingxia Li iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c01970 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zonglong Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai201203, China. Hauptthemen laut MEDLINE: p300-CBP Transcription Factors, Small Molecule Libraries, E1A-Associated p300 Protein. Die Arbeit nennt 161 Literaturangaben. Gefördert von: Qingdao National Laboratory for Marine Science and Technology, Program of Shanghai Leading Talent Program of Eastern Talent Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

p300 and its paralog CBP are multifunctional transcriptional coactivators that play central roles in epigenetic regulation by integrating diverse signaling pathways. Dysregulation of p300/CBP is closely linked to cancer and other diseases, rendering them attractive therapeutic targets. Several small-molecule inhibitors of p300/CBP, including CCS1477 and FT-7051, have advanced into clinical trials for cancer treatment. In this perspective, we provide a comprehensive overview of small-molecule inhibitors targeting the bromodomain and catalytic domain of p300/CBP, with particular emphasis on their optimization processes. Furthermore, the landscape of p300/CBP-targeted drug discovery has evolved from conventional inhibitors to sophisticated bifunctional proximity-inducing modalities. We discuss the transformative impact of bifunctional molecules targeting p300/CBP, including PROTACs, AceTAGs, RIPTACs, DALTACs, and TCIPs. Finally, we discuss current limitations and challenges and offer perspectives on future directions. This perspective aims to provide a strategic roadmap for the development of next-generation therapeutics targeting p300/CBP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

p300-CBP Transcription FactorsSmall Molecule LibrariesE1A-Associated p300 ProteinHumansAnimalsDrug DiscoveryProteolysis Targeting Chimera

Stichwörter der Autor:innen

bifunctional proximity-inducing modalitybromodomainhistone acetyltransferasep300/CBPsmall-molecule inhibitortranscriptional coactivator

Substanzen

p300-CBP Transcription FactorsSmall Molecule LibrariesEP300 protein, humanE1A-Associated p300 ProteinProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai201203, China.
  • Lingang Laboratory, Shanghai200031, P. R. China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai201210, China.
  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai200240, China.
  • School of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu210023, China.

ORCID-Profile: Zonglong Chen, Yingxia Li

Förderung

  • Qingdao National Laboratory for Marine Science and Technology
  • Program of Shanghai Leading Talent Program of Eastern Talent Plan

Zitieren

APA

Chen, Z., Huang, X., & Li, Y. (2026). Targeting Transcriptional Coactivators p300/CBP: Small-Molecule Inhibitors or Bifunctional Proximity-Inducing Modalities?. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01970

Vancouver

Chen Z, Huang X, Li Y. Targeting Transcriptional Coactivators p300/CBP: Small-Molecule Inhibitors or Bifunctional Proximity-Inducing Modalities?. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01970

BibTeX
@article{Chen2026,
  author = {Chen, Zonglong and Huang, Xun and Li, Yingxia},
  title = {Targeting Transcriptional Coactivators p300/CBP: Small-Molecule Inhibitors or Bifunctional Proximity-Inducing Modalities?},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01970}
}
Kostenlos starten →